Grafa News and Videos — Page 1050

Pfizer (NYSE:PFE) and Astellas announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for the perioperative use of Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab).

Digi Power X (NASDAQ:DGXX) announced today that it has signed a 24-month bare metal GPU rental agreement with SubQ AI, a move that formally validates the commercial launch of its proprietary NeoCloudz infrastructure.

NANO-X IMAGING (NASDAQ:NNOX), an innovative medical imaging technology company, today reported financial results for the fourth quarter ended December 31, 2025.

MainStreet Bancshares (NASDAQ:MNSB), the holding company for MainStreet Bank, today reported net income of $4.1 million, or $0.48 per diluted common share, for the quarter ended March 31, 2026.

YY Group Holding (NASDAQ:YYGH), a data-driven human resources and business process outsourcing provider, today reported its unaudited financial results for the fiscal year ended December 31, 2025.

QuidelOrtho (NASDAQ:QDEL), a global powerhouse in in vitro diagnostics, has announced the acquisition of LEX Diagnostics.

AstraZeneca (NASDAQ:AZN) today announced positive high-level results from its pivotal Phase III MIRANDA trial, evaluating tozorakimab as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).

Clearmind Medicine (NASDAQ:CMND), a clinical-stage pharmaceutical company focused on developing novel psychedelic-derived therapies, announced today that its lead candidate, CMND-100, has successfully met the primary safety and tolerability endpoints in its Phase I/IIa clinical trial.

Capital City Bank Group (NASDAQ:CCBG) today reported financial results for the first quarter ended March 31, 2026, delivering a consistent performance characterized by disciplined expense management and improved capital metrics.

Biogen (NASDAQ:BIIB) announced today that it has entered into a definitive agreement to acquire the exclusive Greater China rights for felzartamab from TJ Biopharma.